BHVN
HealthcareBiohaven Ltd. · Biotechnology · $1B
What is Biohaven Ltd.?
Biohaven Ltd. is a clinical-stage biopharmaceutical company headquartered in New Haven, focused on developing treatments for neurological and immunoscience diseases. It aims to shift how difficult conditions are managed through novel therapeutic approaches.
Biohaven generates no commercial revenue in the traditional sense — as a clinical-stage company, its work centers on advancing drug candidates through research and clinical trials rather than selling approved products at scale. The company targets neurological and immunoscience diseases where existing treatments leave significant unmet needs. Its business model depends on successfully developing therapies that can alter current treatment paradigms, with value creation tied to pipeline progress and eventual regulatory approvals.
Biohaven Ltd. was established in 2022 and is headquartered in New Haven, US.
- Neurological disease therapy development
- Immunoscience disease research programs
- Clinical-stage drug pipeline advancement
- Treatment paradigm innovation in rare and complex diseases
Is BHVN a Good Stock to Buy?
UQS Score rates BHVN as Poor overall, reflecting meaningful challenges across most evaluated dimensions.
Among the five pillars, Risk comes in at a Neutral rating — the lone area where BHVN does not register at the weakest level. This suggests the company's risk profile, while not strong, is not at an extreme relative to clinical-stage peers.
Quality, Moat, and Growth all carry Weak ratings, pointing to the absence of durable competitive advantages and limited evidence of near-term revenue generation. Valuation is rated Elevated, meaning the current price reflects optimism that the pipeline has not yet substantiated.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BHVN pay dividends?
No — Biohaven Ltd. does not currently pay a dividend.
Biohaven does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding research, clinical trials, and pipeline development. Investors in BHVN are accepting near-term income sacrifice in exchange for potential long-term value creation if drug candidates succeed.
When does BHVN report earnings?
Biohaven reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly reports focus primarily on cash runway, research and development expenditures, and pipeline milestones rather than product revenue. Progress in clinical trials and regulatory updates tend to be the most market-moving disclosures.
For the most current quarterly results and pipeline updates, visit Biohaven's official investor relations page.
BHVN Price History
+61.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
BHVN Long-term Outlook
The fundamental outlook for BHVN is shaped by its Weak Growth and Weak Quality pillar ratings, which reflect the inherent uncertainty of a company without approved commercial products. Progress is binary in nature — pipeline success could materially change the trajectory, while setbacks could erode value quickly. The Elevated Valuation rating suggests the market is already pricing in a degree of optimism, which raises the bar for pipeline execution. The Neutral Risk rating provides modest reassurance that downside scenarios are not considered extreme relative to the clinical-stage peer group.
Growth drivers
- Advancement of neurological disease candidates through clinical trials
- Potential regulatory milestones unlocking commercial opportunity
- Expanding focus into immunoscience as a second growth vector
Key risks
- Clinical trial failure or regulatory setbacks with no commercial revenue buffer
- Elevated valuation leaving limited margin of safety if pipeline disappoints
- Ongoing capital requirements typical of pre-revenue biopharmaceutical companies
BHVN vs Peers
Biohaven operates in a competitive clinical-stage biopharma landscape alongside several peers also navigating the path from research to regulatory approval.
Septerna focuses on G protein-coupled receptor biology, pursuing a distinct mechanistic approach compared to Biohaven's neurological and immunoscience focus.
Savara concentrates on rare pulmonary diseases, giving it a narrower therapeutic focus than Biohaven's broader neurological and immunoscience pipeline.
GH Research targets treatment-resistant psychiatric conditions using psychedelic-derived compounds, representing a different therapeutic modality than Biohaven's approach.
Frequently Asked Questions
What does Biohaven Ltd. do?
Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and immunoscience diseases. It does not yet sell approved commercial products — its value is tied to advancing a pipeline of drug candidates through clinical trials and toward regulatory approval.
Does BHVN pay dividends?
No, Biohaven does not pay a dividend. Clinical-stage companies typically reinvest all available capital into research and development. Investors should not expect income distributions while the company remains pre-commercial.
When does BHVN report earnings?
Biohaven reports on a quarterly cadence like other US-listed public companies. Because it is pre-revenue, reports focus on cash position, R&D spending, and pipeline updates rather than product sales. Check Biohaven's investor relations page for the current schedule.
Is BHVN a good stock to buy?
UQS Score rates BHVN as Poor, with Weak ratings across Quality, Moat, and Growth, and an Elevated Valuation. This profile reflects the high uncertainty typical of clinical-stage companies. Whether it suits a portfolio depends on individual risk tolerance and investment goals — the full pillar breakdown is available to Pro members.
Is BHVN overvalued?
The UQS Valuation pillar rates BHVN as Elevated, suggesting the current market price reflects meaningful optimism about pipeline outcomes. For a pre-revenue company, valuation is inherently speculative and tied to clinical and regulatory milestones rather than current earnings.
How does BHVN compare to its competitors?
Biohaven competes in the clinical-stage biopharma space alongside companies like Septerna, Savara, and GH Research. Each pursues different therapeutic areas and mechanisms. UQS Score evaluates each independently — see the competitor pages for side-by-side pillar comparisons.
What is BHVN's market cap bracket?
Biohaven is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is common for clinical-stage biopharmaceutical companies.
Who founded Biohaven Ltd.?
Biohaven Ltd. was established in 2022 and is headquartered in New Haven, US. For detailed founding history and leadership background, the company's official website and SEC filings are the most reliable sources.
Is BHVN a long-term quality investment?
As a long-term quality indicator, the UQS Score rates BHVN as Poor. Weak Quality and Moat ratings suggest the company has not yet established the durable competitive advantages associated with long-term compounders. Pipeline success could change this trajectory, but current fundamentals reflect early-stage risk.
What is the main competitive advantage of Biohaven?
Biohaven's potential advantage lies in its focus on underserved neurological and immunoscience conditions where existing treatments are limited. However, the UQS Moat pillar currently rates this as Weak, reflecting that no durable commercial moat has been established while the company remains in clinical development.
What sector does BHVN belong to?
Biohaven operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. This segment is characterized by binary outcomes tied to clinical trial results and regulatory decisions rather than steady revenue growth. Explore more [Healthcare sector stocks](/sector/healthcare) on UQS Score.
Is BHVN a growth stock or value stock?
Based on UQS pillar ratings, BHVN does not fit neatly into either category. The Growth pillar is rated Weak and Valuation is Elevated, meaning it carries a premium price without demonstrated growth to support it — a profile more common in speculative early-stage names than traditional growth or value stocks.
Unlock Full BHVN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare BHVN against clinical-stage peers side by side
- ✓Screen for higher-quality Healthcare sector alternatives
- ✓Get the full analyst view available to Pro members
Pro Analysis
BHVN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 15.1 | 0.0 | 13.0 | 15.0 | 58.8 | 0.0 | +3.0 |
| May 9, 2026 | 12.1 | 0.0 | 13.0 | 0.0 | 58.8 | 0.0 | -3.0 |
| Apr 22, 2026 | 15.1 | 0.0 | 13.0 | 15.0 | 58.8 | 0.0 | -0.7 |
| Apr 2, 2026 | 15.8 | 0.0 | 13.0 | 18.8 | 58.8 | 0.0 | — |
BHVN — Pillar Breakdown
Quality
— 0.0/100 (25%)Biohaven Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 15.0/100 (20%)Biohaven Ltd. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 58.8/100 (15%)Biohaven Ltd. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Biohaven Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Biohaven Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BHVN.
Score Composition
Financial Data
More Stock Analysis
How is the BHVN UQS Score Calculated?
The UQS (Unified Quality Score) for Biohaven Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Biohaven Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Biohaven Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.